Foveal LLP Independent Investment Research Foveal Research

With the recent approval of Roche’s paroxysmal nocturnal haemoglobinuria (PNH) orphan drug C5 inhibitor Piasky, with its unique subcutaneous delivery, as well as Novartis’s alternative Factor B mechanism of action oral Fabhalta potentially changing the treatment paradigm in PAH , we assess the prospects of the various complement inhibitors in PNH and find oral Fabhalta data compelling and see significant hurdles for Roche’s subcutaneous self-administered Piasky

Following ASCO 24, we update our detailed analysis of the current phase late-stage data from AZN/Daiichi’s TROPION Gilead’s EVOKE and MRK